XOMA (3.99, +27% in past 2 days) continues yesterday’s rally on the heels of another good webcast this morning at Credit Suisse. There was not as much clinical detail as on yesterday’s 1Q13 CC (there was only half as much time); however, the CMO, Paul Rubin (who may read this board) went out of his way to say that Gevokizumab’s allosteric modulation of the IL-1beta receptor allows for sufficient IL-1 to get through to IL-1’s orthosteric receptor to handle the body’s needs during a severe infection or other event requiring a heightened immune response.
Market Data 
Markets 
AI
